A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer

Mutations in TP53 lead to a defective G1 checkpoint and the dependence on checkpoint kinase 1 (Chk1) for G2 or S phase arrest in response to DNA damage. In preclinical studies, Chk1 inhibition resulted in enhanced cytotoxicity of several chemotherapeutic agents. The high frequency of TP53 mutations...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ma, Cynthia X., Ellis, Matthew J. C., Petroni, Gina R., Guo, Zhanfang, Cai, Shi-rong, Ryan, Christine E., Craig Lockhart, A., Naughton, Michael J., Pluard, Timothy J., Brenin, Christiana M., Picus, Joel, Creekmore, Allison N., Mwandoro, Tibu, Yarde, Erin R., Reed, Jerry, Ebbert, Mark, Bernard, Philip S., Watson, Mark, Doyle, Laurence A., Dancey, Janet, Piwnica-Worms, Helen, Fracasso, Paula M.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2012
Assuntos:
Clinical Trial
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3539064/
https://ncbi.nlm.nih.gov/pubmed/23242585
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-012-2378-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados